Article · 29 Mar 2024
Conference abstract
Intentional medication errors: Off-label use?
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
To obtain a marketing authorisation (MA), companies are expected to evaluate the safe use of their medicinal product. In the risk management plan, dedicated sections address medication errors and off-label use; two sides of the same coin: the authorized product information guidance is not followed, either inadvertently (in error) or intentionally. Several initiatives are currently taking place to monitor medication errors, e.g. to develop a medication error SMQ; and the EMA has published good practice guides on coding and reporting, and on risk minimization and prevention. The balancing line between product usages that categorizes as medication errors versus off-label use is thin, and may be drawn differently by different MAHs, also depending on the authorized indications for their specific products. How often is it clear from the reported information that the ?off-label? administration indeed occurred intentionally? How to code reports where a patient intentionally takes a product for longer than is written in the product information? Also, the same active substance, usually the level on which signal detection activities occur, can be authorised for multiple indications. This means that if signalling activities occur by different stakeholders, different results will be obtained. Finally, where the concept of medication errors includes an unintended error or failure in the drug treatment process, the concept of off-label refers to an intention to not use the product according to the authorised indication. How should this be managed?
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Article · 11 Feb 2026
Off-Label Use of Vonoprazan and Mosapride for Management of Gastroesophageal Reflux in a Dog with Megaesophagus
Review article · 1 Mar 2022
A Systematic Review of Off-Label Use of Memantine for Neuropsychiatric Disorders Other than Dementia
Review article · 2021
Off-label Prescribing Practice in Pediatric Settings: Pros and Cons
Conference abstract · 17 Jul 2017
Is the current analysis of MAHs of ‘off-label use’ constructive?
More from this journal
The newest in Journal of Pharmacovigilance.
Article · 19 Jun 2026
Advancing Patient Safety Through Modern Pharmacovigilance Practices
Article · 19 Jun 2026
Strengthening Healthcare Outcomes Through Effective Drug Safety Practices
Article · 19 Jun 2026
Expanding Patient Care Through Clinical Pharmacy Services in Modern Healthcare
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacovigilance
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Angela van der Salm”

